港股異動 | 機構扎堆唱好 信達生物(1801.HK)一度漲超10%
格隆匯2月10日丨信達生物(1801.HK)盤中一度漲超10%,現報34.05港元,總市值498億港元。今日FDA將召開信達/禮來合作的PD-1藥物信迪利單抗上市申請的ODAC會議(腫瘤藥物諮詢委員會)。事實上,細數創新管線與臨牀進展,信達生物已經是與國際接軌,與國際創新巨頭藥企並肩前行。另外,近日公司持續獲投行唱好。野村維持其“買入”評級,目標價看高至92.73港元;高盛維持買入評級,目標價84.7港元,國泰君安亦維持信達生物“增持”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.